B cell chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western hemisphere, yet many biological and molecular features of the disease remain undefined. CLL cells generate increased levels of radical species such as superoxide and nitric oxide (NO), which is associated with mitochondrial DNA mutations. Considering that NO levels can affect mitochondrial biogenesis, we hypothesized that the inherent nitrosative stress in CLL cells may lead to hyperactive mitochondrial biogenesis. Here we report that primary CLL cells contained significantly more mitochondria than normal lymphocytes and that their mitochondrial mass was significantly related to endogenous NO levels. Expression of the mitochondrial biogenesis factors nuclear respiratory factor-1 and mitochondrial transcription factor A was elevated in most CLL specimens examined and appeared to be related to cellular NO levels. Treatment of B cells with exogenous NO caused a substantial increase in mitochondrial mass. In vitro sensitivity of CLL cells to fludarabine was highly related to mitochondrial mass in that cells with greater mitochondrial mass were less sensitive to the drug. Taken together, our results suggest that NO is a key mediator of mitochondrial biogenesis in CLL and that modulation of mitochondrial biogenesis by NO may alter cellular sensitivity to fludarabine.
Introduction
B cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western hemisphere. This particular malignancy is distinguishable from many other types of hematological cancers in that the disease course involves a continuous rise in lymphocyte counts, most likely due to defects in the apoptotic machinery rather than increased cell proliferation. 1 In spite of the prevalence of CLL, many of the biochemical and molecular features of the disease remain to be characterized. A major obstacle in CLL research is the lack of an appropriate cell line model. As such, primary CLL cells from patients, which tend to undergo spontaneous apoptosis in culture, must be used in order to gain further insight into the disease. Our earlier work demonstrated that primary CLL cells generate elevated levels of the oxygen radical superoxide (O 2 À ) and are under increased oxidative stress, which seems to be associated with mitochondrial DNA (mtDNA) mutations and alterations in drug sensitivity. [2] [3] [4] Mitochondrial defects such as these in addition to alterations in energy metabolism and diminished apoptotic capacity appear to be general features of cancer cells regardless of tumor type. 5, 6 Certain malignant cells have also been reported to have alterations in mitochondrial content as compared to normal cells of the same tissue. [7] [8] [9] [10] It has recently been observed that CLL cells exhibit altered expression of inducible nitric oxide synthase (iNOS) associated with increased levels of NO and decreased sensitivity to apoptosis induction. 11 Since cellular energy metabolism and ROS/RNS (especially NO levels) can significantly affect mitochondrial biogenesis, we hypothesized that CLL cells may display hyperactive mitochondrial biogenesis. The present study was conducted to test this possibility, to identify the underlying mechanism, and to evaluate whether mitochondrial mass has an impact on sensitivity to anticancer agents.
Materials and methods

Cells and cell culture
Peripheral blood samples were obtained from CLL patients and healthy donors after appropriate informed consent. CLL cells or normal lymphocytes were isolated from blood specimens using a Ficoll density centrifugation method. 12 Cells were resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum and incubated at 371C in a humidified incubator with 5% CO 2 . Normal B lymphocytes were purified from the blood samples of healthy donors by a negative selection method using the RosetteSep s B Cell Enrichment Cocktail (Stem Cell Technologies, Vancouver, BC, Canada). 13 Raji cells (B cell lymphoma) and EBV-transformed human B lymphocytes were cultured under the same conditions. Exposure to exogenous NO was accomplished by daily treatment with 100 mM SNAP (Snitroso-N-acetylpenicillamine) for 3 consecutive days as described.
14 Suppression of endogenous NO production was achieved by treatment with 1 mM L-NMMA (N G -methyl-Larginine), a general NO synthase inhibitor (Molecular Probes, Eugene, OR, USA) for 3 consecutive days. Mitochondrial mass of both SNAP and L-NMMA-treated cells was assessed on day 4 as described below.
Transmission electron microscopy
Normal lymphocytes and primary CLL cells were fixed as previously described. 15 Ultrathin sections were cut in an LKB Ultracut microtome (Leica, Deerfield, IL, USA), stained with uranyl acetate and lead citrate in an LKB Ultrostainer, and examined in a JEM 1010 transmission electron microscope (TEM) (JEOL, USA, Inc., Peabody, MA, USA) at an accelerating voltage of 80 kV. Digital images were obtained using the AMT Imaging System (Advanced Microscopy Techniques Corp, Danvers, MA, USA).
Analysis of basal NO and mitochondrial mass
Basal NO production was determined by flow cytometric analysis using DAF-FM (Molecular Probes, Eugene, OR, USA). Mitochondrial mass was measured by flow cytometric analysis using Mitotracker Green, which preferentially accumulates in mitochondria regardless of the mitochondrial membrane potential status. [16] [17] [18] Cells were stained in Krebs-Ringer buffer with 1 mM DAF-FM or in culture medium containing 100 nM Mitotracker Green for 60 min at 371C. Fluorescence was quantified using the FL-1H channel on a FACSCalibur flow cytometer (Becton-Dickinson). The relative cellular NO levels or mitochondrial contents were expressed as relative fluorescent units (RFU). To ensure the comparability of data obtained at different times, identical cytometer settings were used each time and calibrated using a reference cell line (Raji).
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) analyses
RNA was isolated from CLL cells and normal lymphocytes using the RNeasy kit and reverse transcribed using the Omniscript RT kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. cDNA was amplified using standard PCR conditions as previously described. 2 Primer sequences used are as follows:
In vitro sensitivity to fludarabine nucleoside
Freshly isolated CLL cells were treated with various concentrations of 9-b-D-arabinofuranosyl-2-fluoro-adenine (F-ara-A, the nucleoside form of fludarabine for in vitro study, Sigma) ranging from 0.1 to 30 mM for 72 h. Viability of CLL cells following drug exposure was determined by the MTT assay as previously described. 3 
Statistical analyses
Mann-Whitney tests were used to determine the significance of differences in the numbers of mitochondria between normal lymphocytes and primary CLL cells. Spearman's test was used to analyze the correlation between NO and mitochondrial mass and the correlation between in vitro fludarabine sensitivity and mitochondrial mass. The Kolmogorov-Smirnov test was used to evaluate differences between the control and test samples when determining the effects of exogenous NO and L-NMMA on B cells. A P-value of less than 0.05 was considered statistically significant.
Results and discussion
Primary CLL cells contain significantly more mitochondria than normal lymphocytes The mitochondrial mass of CLL cells is significantly related to the levels of endogenous NO
We next sought to investigate the potential mechanism for the increased numbers of mitochondria observed in CLL cells. Mitochondrial biogenesis can be stimulated by such factors as cell proliferation, hypothermia, gluconeogenesis and elevated cellular levels of NO. 14, 19, 20 Considering that CLL cells in peripheral blood are predominantly quiescent and have been shown to exhibit abnormal regulation of iNOS, 11, 21 we hypothesized that NO would be a likely stimulus of mitochondrial biogenesis in CLL. To test this hypothesis, we analyzed the relationship between cellular NO levels and mitochondrial mass in primary CLL cells from 20 patients (Figure 2a) . Statistical analysis revealed a highly significant relationship between the levels of NO and the mitochondrial mass in the patient cells (r ¼ 0.8455, Po0.0001), suggesting that NO indeed may be mediating the increased mitochondrial biogenesis in CLL. To our knowledge, these data provide the first evidence implicating the role of nitric oxide in the mitochondrial biogenesis of primary malignant cells.
Elevated mRNA expression of mitochondrial biogenesis factors in primary CLL cells
Nitric oxide stimulates mitochondrial biogenesis through a cyclic GMP-mediated pathway involving activation of key mitochondrial biogenesis factors.
14 To determine whether the increased numbers of mitochondria in CLL cells could be a consequence of aberrant mitochondrial biogenesis factor expression, we used RT-PCR to examine the relative mRNA expression levels of three such factors in unfractionated normal lymphocytes (B and T), isolated normal B lymphocytes and primary CLL cells. The following three mitochondrial biogenesis factors were assayed: nuclear respiratory factor-1 (NRF-1), peroxisome proliferator-activated receptor g co-activator-1 (PGC-1) related coactivator (PRC) and mitochondrial transcription factor A (TFAM). NRF-1 activates the transcription of the majority of the nuclear-encoded subunits of the electron transport chain in addition to TFAM, which is responsible for the transcription of mtDNA-encoded genes. PRC is a transcriptional co-activator that binds to NRF-1 and enhances its transcriptional activity. Alterations in the expression of all three of these factors have been shown to modulate mitochondrial biogenesis activity. 19, [22] [23] [24] RT-PCR analyses revealed that the expression of NRF-1 and TFAM was markedly higher in the majority (eight of 10) CLL patients as compared to the normal lymphocytes, whereas the expression of PRC appeared unchanged in all cases (Figure 2b ). Considering that NRF-1 activates the transcription of TFAM, it is not surprising that TFAM expression would also be elevated in cells with higher basal NRF-1 expression. Notably, the relative expression of NRF-1 seemed to be correlated with basal NO levels. For instance, NRF-1 expression was lowest in the patients with the lowest NO levels (CLL #1 and #4, Figure 2b , lanes 4 and 7) and higher in other patients whose NO levels were also higher.
The expression of NRF-1 was particularly high in the patients with the highest NO levels (Figure 2b, lanes 5 and 9) . These data support the hypothesis that NO is an important mediator in stimulating mitochondrial biogenesis in primary CLL cells.
Exogenous NO causes increased mitochondrial mass in B-cells
Our analyses of normal lymphocytes and primary CLL cells demonstrated that the increased mitochondrial mass of CLL cells appeared to be linked to the levels of endogenous NO and overexpression of key NO-activated biogenesis factors. To provide further evidence that NO is a relevant activator of mitochondrial biogenesis in B cells, we used two human B cell lines (Raji B cell lymphoma and a clone of EBVtransformed B lymphocytes) to test the ability of exogenous NO to stimulate mitochondrial proliferation. Cells were treated with the NO donor SNAP (100 mM) daily for 3 days and the consequent effects on mitochondrial mass were assessed. SNAP treatment caused a marked, highly significant increase in mitochondrial mass in both cell lines. Specifically, the mitochondrial mass in SNAP-treated Raji and EBV-B cells was approximately 200 and 250% of the control cells, respectively (Figure 3a, b) . In order to confirm the effects of NO on mitochondrial biogenesis, we fixed a portion of control and SNAP-treated Raji cells from these experiments and analyzed their mitochondrial content using TEM. The cells subjected to SNAP treament (Figure 3d ) had substantially more mitochondria than control cells (Figure 3c ). These data indicate that NO can act as a driving force of mitochondrial biogenesis in B cells. The daily treatment of cells with 100 mM SNAP for 3 days showed a minor cytotoxic effect in approximately 25% of the cells.
Inhibition of NO synthase activity leads to reduced mitochondrial mass
As our experiments showed that increasing the cellular NO content through treatment with SNAP resulted in a substantial increase in the mitochondrial mass of cultured B cells, we reasoned that reducing the basal NO generation of B cells would lead to a reduction in mitochondrial mass. To test this possibility, we treated Raji cells with a subtoxic concentration (1 mM) of the NO synthase inhibitor, L-NMMA, daily for 3 consecutive days and then assessed the cellular NO contents and the effect on mitochondrial mass. Flow cytometric analysis showed that exposure of Raji cells to 1 mM L-NMMA decreased the endogenous NO levels by nearly 45% (data not shown), and caused an approximately 20% reduction of the mitochondrial mass (Figure 3e, Po0.001) . These results further demonstrate the importance of NO in the regulation of mitochondrial mass of B cells.
Mitochondrial mass in primary CLL cells is significantly correlated with drug sensitivity in vitro
Our initial analysis of the mitochondrial mass of primary CLL cells revealed that the mass of cells from different patients varies significantly (Figure 2a) . Considering the important role of mitochondria in regulating apoptosis including drug-induced cell death, we next tested the possibility that alterations in mitochondrial mass in CLL cells might affect sensitivity to chemotherapeutic agents. F-ara-A, the nucleoside form of fludarabine (an agent commonly used in the clinical treatment of CLL), was used to test the in vitro drug sensitivity of primary leukemia cells isolated from 16 CLL patients. The nucleoside analog F-ara-A readily enters the cells, where it is phosphorylated first to 5 0 -monophosphate (fludarabine), and then to diphosphate and triphosphate forms to exert its pharmacological action. 25, 26 An analysis of the relationship between the in vitro drug sensitivity (IC 50 ) and the mitochondrial mass of individual patient cells revealed a highly significant correlation between the two parameters (Figure 4 , Po0.0001). CLL cells with higher mitochondrial mass were less sensitive to fludarabine nucleoside. These data suggest that the aberrant mitochondrial biogenesis and abnormal accumulation of mitochondrial mass in CLL may compromise the apoptotic response in CLL cells. Although the exact mechanism responsible for the reduced drug sensitivity is unknown at the present time, the abnormal increase of NO and accumulation of mitochondrial mass in CLL cells likely contribute to the development of drug resistance and, thus, may have clinical implications.
Our studies demonstrate that CLL cells contain significantly more mitochondria than normal lymphocytes. Within the group of CLL patients analyzed, we found that the mitochondrial mass of individual samples was highly related to endogenous NO levels and that the mRNA expression of the mitochondrial biogenesis factors NRF-1 and TFAM in the majority of CLL cells was notably higher than normal lymphocytes. Exposure of B cells to exogenous NO in culture consistently caused a substantial increase in the mitochondrial mass. Furthermore, inhibition of NO synthase activity led to a reduction of mitochondrial mass in cultured B cells. We also attempted to test the effect of SNAP on mitochondrial mass in primary B-CLL cells isolated from patients, but such experiments failed due to the inability of CLL cells to sustain a relatively long-term culture (3-4 days). High rates of spontaneous apoptosis were observed in CLL cells within 2-3 days of culture in vitro. Three major forms of NO synthases have been characterized in mammalian cells to date: endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS). Both eNOS and nNOS are constitutively expressed and regulated by specific phosphorylation, whereas the activity of iNOS is modulated through transcriptional regulation of its expression. Alterations in the activity of all three of these enzymes can significantly affect cellular NO levels. 27 The existence of a mitochondrial-specific form of NOS (mtNOS) has been proposed in recent years. 28, 29 However, it is still unclear whether this mitochondrial NOS enzyme is functionally distinguishable from eNOS, nNOS and iNOS. Studies conducted in NOS-deficient mice suggested that eNOS deficiency has the most profound effect on mitochondrial biogenesis and energy metabolism. Mice lacking eNOS have significantly fewer mitochondria, poor energy metabolism and increased body mass as compared to wild-type mice. 14 However, the role of mtNOS in regulating mitochondrial biogenesis remains unclear at the present time. Further studies are required to characterize mtNOS expression in malignant cells and determine the relationship between mtNOS expression and mitochondrial mass.
It is of interest to note that the expression of iNOS, an enzyme responsible for NO generation, can be induced by ROS stress, which is frequently observed in CLL cells. 3, 4, 30, 31 Additionally, these studies shed new light on a potential consequence of oxidative and nitrosative stress, which has been reported in many tumor types. Our findings provide evidence directly obtained from clinical specimens implicating the important role of nitric oxide in mitochondrial biogenesis in primary malignant cells. As mitochondrial play an essential role in generation of ATP, integration of various metabolic pathways and regulation of apoptosis, the significant increase of mitochondrial mass in CLL cells is likely to cause alterations in these biological events and may play a role in the pathological process of CLL. In particular, our study revealed a significant correlation between an aberrant increase of mitochondrial mass and decreased in vitro drug sensitivity. As such, it may be possible to alter the NO-mediated mitochondrial biogenesis in CLL cells by inhibiting nitric oxide synthases to decrease NO production and enhance the cellular response to treatment with anticancer agents such as fludarabine. The clinical significance of mitochondrial alterations relevant to the survival of CLL cells and their therapeutic implications warrants future investigation. In vitro sensitivity of CLL cells to fludarabine nucleoside is significantly correlated with mitochondrial mass. CLL cells freshly isolated from 16 patients were treated with various concentrations of fludarabine nucleoside (F-ara-A) for 72 h. MTT assay was used to determine cell viability following drug treatment. The relationship between the drug sensitivity (IC 50 ) and the mitochondrial mass of individual patient cells is plotted with linear regression (r ¼ 0.8265, Po0.0001). The IC 50 value is the drug concentration (mM) that caused a 50% loss of cell viability. Mitochondrial mass was measured by flow cytometric analysis after the cells were labeled with Mitotracker Green, and expressed as relative fluorescent units (RFU) as described in Materials and methods.
